• Preliminary report

Sponsored Links

  • FileName: preliminary_report_2010.pdf [preview-online]
    • Abstract: 2010Preliminary reportAvançament memòriaAvance memoria 2010PresentationPresentacióPresentaciónA passion for quality researchPassió per la recerca de qualitatPasión por la investigación de calidad

Download the ebook

Preliminary report
Avançament memòria
Avance memoria
A passion for quality research
Passió per la recerca de qualitat
Pasión por la investigación de calidad
The Bellvitge Biomedical Research Institute (IDIBELL) is the centre that manages the
research carried out by professionals working at Bellvitge University Hospital, Duran
i Reynals Hospital (ICO), and the Bellvitge Campus of the University of Barcelona.
IDIBELL is supported by the Catalan Institute of Health (ICS), the Catalan Institute of
Oncology (ICO), the University of Barcelona, and the Institute for Diagnostic Imaging.
IDIBELL is strategically located in Biopol’H, a science and health park in L’Hospitalet
de Llobregat.
IDIBELL is a young institution nourished by the experience of the research institu-
tions that were its predecessors on the Bellvitge Campus, one of the areas of Spain
with the highest level of academic and clinical excellence. In this setting, IDIBELL has
the opportunity to carry out research activities aimed at solving health problems.
IDIBELL’s research activity has grown considerably, and currently it is the second most
important health research institute in Spain.
In 2010, IDIBELL researchers In 2010, IDIBELL continued to pursue its commitment to quality research aimed at
improving people’s health. Researchers at the Institute continued to publish in the
continued to publish in the best
best scientific journals and participate in leading national and international research
scientific journals and participate projects.
in leading national and The Institute set up a department to promote knowledge transfer to ensure that
international research projects the results of work done by its researchers are applied. This work depends on the co-
llaboration of many other institutions. In this regard, in 2010 IDIBELL strengthened its
L’any 2010, els investigadors de institutional agreements and was integrated into new research networks. In the field of
l’IDIBELL han continuat publicant clinical trials, IDIBELL strengthened its participation in CAIBER (Consortium to Support
Biomedical Research Network). The Institute also participates in the Health Universitat
en les millors revistes científiques de Barcelona Campus (HUBc), which is accredited as an International University Cam-
i liderant projectes nacionals i pus by the Spanish Government.
internacionals rellevants In 2010, IDIBELL continued work on the Biobank project, which will become one of
the largest sample collections in Spain. Biobanks are essential resources to carry out
El año 2010, los investigadores research with a high scientific and social impact, and this is one of the institution’s
del IDIBELL han continuado main strategic projects.
This year, IDIBELL began to define its strategic plan for the coming years and rethink
publicando en las mejores its research areas. The development of the plan involves the participation of the
revistas científicas y liderando Institute’s researchers. IDIBELL is also firmly committed to quality management and
proyectos nacionales e has started to adapt support services for accreditation under ISO standards.
internacionales relevantes The overview provided here presents the main highlights of 2010. Please take a mo-
ment to read through it, and feel free to visit our website for more information.
Emilià Pola
IDIBELL General Manager
Cancer cells hijack and inactivate tumour molecules within
their own core
Les cèl·lules del càncer segresten i inactiven molècules
antitumorals dins dels seus propis nuclis
Las células del cáncer secuestran e inactivan moléculas
antitumorales dentro de sus propios núcleos
In a subgroup of tumours of the colon, stomach and uterus, cancer cells hijack a group
of anti-tumour molecules within their core, preventing them from maturing and per-
forming their function in the cell, according to a study conducted by the Cancer Epi-
genetics and Biology programme at IDIBELL and published in the journal Cancer Cell.
Researcher Manel Esteller, the coordinator of the study, explains that “these results
have implications for improving our understanding of the causes of cancer, but also for
possible new treatments. There are two reasons for this: first, we’ve discovered a new,
previously unknown way in which cancer cells are altered; and second, there’s a new
molecular target, which should stimulate the search for new drugs that improve the
transport of molecules from the nucleus.”
Paper published by IDIBELL researchers is the world’s most
influential in biology, according to Science Watch
Un article publicat per investigadors de l’IDIBELL és el més
influent del món en Biologia, segons Science Watch
Un artículo publicado por investigadores del IDIBELL es el
más influyente del mundo en Biología, según Science Watch
A study carried out by researchers at IDIBELL is the most frequently cited in the biology
category, according to Thomson Reuters’ Science Watch ranking for November and
December 2010. The number of times an article is cited in other papers indicates its in-
fluence in science. The article “Antiangiogenic therapy elicits malignant progression of
tumours to increased local invasion and distant metastasis”, based on research led by
the researcher Oriol Casanovas, was published in the March 2009 issue of Cancer Cell.
Mechanism that explains the common properties of stem
cells and cancer cells identified
Identificat un mecanisme que explica les propietats comunes
entre les cèl·lules mare i les cèl·lules canceroses
Identificado un mecanismo que explica las propiedades
comunes entre las células madre y las células cancerosas
A study published in the journal Proceedings of the National Academy of Sciences
(PNAS) identifies a mechanism that explains the common properties shared by stem
cells and cancer cells. The work was done by the Cancer Epigenetics Research Group,
led by Manel Esteller, an ICREA researcher at IDIBELL.
AECC promotes research on hereditary cancer at IDIBELL
La AECC impulsa la recerca en càncer hereditari de l’IDIBELL
La AECC impulsa la investigación en cáncer hereditario del
The Scientific Foundation of the Spanish Association Against Cancer (AECC) has awar-
ded €1.2 million for research on hereditary cancer at IDIBELL. The grant was given to
the project “Hereditary cancer: towards an accurate estimate of risk”, led by Gabriel
Capellá, IDIBELL scientific director and director of the Hereditary Cancer Programme of
the Catalan Institute of Oncology (ICO) and IDIBELL.
The project also involved the ICO’s Cancer Prevention Programme, the Medical On-
cology Service at ICO L’Hospitalet de Llobregat, Bellvitge University Hospital (Jordi Pon-
ce and Sebastiano Biondo), and the Institute of Predictive and Personalized Medicine
of Cancer (IMPPC).
Response to monetary gain or loss is determined by brain
La resposta davant dels guanys o les pèrdues monetàries
està condicionada per l’estructura del cervell
La respuesta ante de las ganancias o las pérdidas monetarias
está condicionada por la estructura del cerebro
A great deal of human behaviour is conditioned by mechanisms of reward and punish-
ment, but each person reacts differently to these stimuli. In fact, there are people who
are more likely to seek rewards or pleasures while others show stronger tendencies to
avoid losses or negative life events.
The reason for these individual differences lies in the connections of a specific brain
area, according to a study published in The Journal of Neuroscience. The work involved
Estela Cámara and Antoni Rodríguez Fornells (ICREA researcher), researchers from the
Bellvitge Biomedical Research Institute (IDIBELL) and the Department of Basic Psycho-
logy at the University of Barcelona. The research results provide new evidence on indi-
vidual differences observed in terms of how people can be more or less likely to seek
rewards or pleasures or avoid negative or unpleasant situations.
New data validate effectiveness of a new treatment for
Noves dades validen l’eficàcia d’un tractament contra les
Nuevos datos validan la eficacia de un tratamiento contra las
A new drug for chronic lymphocytic leukaemia and other blood cancers, known as
AICAR (5-aminoimidazole-4-carboxamide riboside), could be a therapeutic alternative
for patients with chronic lymphocytic leukaemia, according to research published in
the journal Blood. The study elucidated the mechanism of action of the drug.
AICAR is the first therapeutic molecule against cancer patented by a Spanish public
centre to have reached the clinical trial stage. The drug was developed in 2003 by
researchers with IDIBELL’s Apoptosis and Cancer Group and the Department of Physio-
logical Sciences II, University of Barcelona (UB), led by Joan Gil. In 2004, the company
Advancell acquired the right to develop and commercialize the product, which is being
produced under the trade name Acadra™.
Pathological complete response predicts a better prognosis
in advanced rectal cancer
La resposta patològica completa prediu un millor pronòstic
en càncer de recte avançat
La respuesta patológica completa predice un mejor
pronóstico en cáncer de recto avanzado
The complete disappearance of cancer cells is the best prognostic factor in locally ad-
vanced rectal cancer, according to a study published in the latest issue of the jour-
nal Lancet Oncology. One of the authors is Sebastiano Biondo, IDIBELL researcher and
head of the Colorectal Unit of Bellvitge University Hospital.
According to the study, among patients with locally advanced rectal cancer treated
with a combination of chemotherapy and radiotherapy and subsequent surgery, the
complete disappearance of detectable cancer cells (known as pathologic complete res-
ponse) after treatment is related to better long-term outcomes than those observed
when pathological complete response is not achieved. Patients with pathological com-
plete response survive more years without disease and have less risk of metastasis.
Board of
Executive Board
Scientific Administrative
IDIBELL comprises more than Direction Management
900 people. Half of them are
employed by the Institute and Cancer & Human
the rest are attached researchers, Mollecular Administration
employed by partners. Genetics
L’IDIBELL està format per més Financial
de 900 persones, de les quals Controller
la meitat estan contractades
per l’institut i la resta són Infectious
investigadors adscrits, contractats Pathology and
per institucions sòcies Transplantments
El IDIBELL está formado por Growth Factors,
más de 900 personas, de Hormones and
las cuales la mitad están Diabetes
contratadas por el instituto
y el resto son investigadores Inflammatory, Chronic
and Degenerative
adscritos, contratados por otras Diseases
instituciones socias
Epigenetics and
Cancer Biology
Scientific production
Producció científica
Producción científica
Scientific publications, indexed with IF* 650
Total impact factor* 3194.11
Average impact factor* 4.91
Projects and current research grants (31st December) 421
Ongoing clinical trials (31st December) 371
R&D contracts 65
Patent applications 2
Licence agreements (out) 1
Total impact factor evolution Average impact factor evolution
*Provisional data
Income structure
Estructura d’ingressos
Estructura de ingresos
IDIBELL receives the most important part
of its financing from competitive sources.
The budget for 2010 was of around 23 mi-
lions of euros. The average time of fun-
ded projects is 3.5 years.
The non-competitive part is the funding
provided by the Government and other
partners. This income structure has not
changed significantly over the last two
20 most representative articles
20 articles més representatius
20 artículos más representativos
Melo, SA; Moutinho, C; Ropero, S; Calin, GA; Rossi, S; Spizzo, R; Fernandez, AF; Davalos,
V; Villanueva, A; Montoya, G; Yamamoto, H; Schwartz, S; Esteller, M.
A Genetic Defect in Exportin-5 Traps Precursor MicroRNAs in the Nucleus of Cancer
Cancel Cell
Pardo, Y; Guedea, F; Aguilo, F; Fernandez, P; Macias, V; Marino, A; Hervas, A; Herruzo,
I; Ortiz, MJ; de Leon, JP; Craven-Bratle, J; Suarez, JF; Boladeras, A; Pont, A; Ayala, A;
Sancho, G; Martinez, E; Alonso, J; Ferrer, M
Quality-of-Life Impact of Primary Treatments for Localized Prostate Cancer in Patients
Without Hormonal Treatment
Journal of Clinical Oncology
Duarte, RF; Canals, C; Onida, F; Gabriel, IH; Arranz, R; Arcese, W; Ferrant, A; Kobbe, G;
Narni, F; Deliliers, GL; Olavarria, E; Schmitz, N; Sureda, A
Allogeneic Hematopoietic Cell Transplantation for Patients With Mycosis Fungoides
and Sezary Syndrome: A Retrospective Analysis of the Lymphoma Working Party of the
European Group for Blood and Marrow Transplantation
Journal of Clinical Oncology
de Sanjose, S; Quint, WGV; Alemany, L; Geraets, DT; Klaustermeier, JE; Lloveras, B;
Tous, S; Felix, A; Bravo, LE; Shin, HR; Vallejos, CS; de Ruiz, PA; Lima, MA; Guimera,
N; Clavero, O; Alejo, M; Llombart-Bosch, A; Cheng-Yang, C; Tatti, SA; Kasamatsu, E;
Iljazovic, E; Odida, M; Prado, R; Seoud, M; Grce, M; Usubutun, A; Jain, A; Suarez, GAH;
Lombardi, LE; Banjo, A; Menendez, C; Domingo, EJ; Velasco, J; Nessa, A; Chichareon,
SCB; Qiao, YL; Lerma, E; Garland, SM; Sasagawa, T; Ferrera, A; Hammouda, D; Mariani,
L; Pelayo, A; Steiner, I; Oliva, E; Meijer, CJLM; Al-Jassar, WF; Cruz, E; Wright, TC; Puras,
A; Llave, CL; Tzardi, M; Agorastos, T; Garcia-Barriola, V; Clavel, C; Ordi, J; Andujar, M;
Castellsague, X; Sanchez, GI; Nowakowski, AM; Bornstein, J; Munoz, N; Bosch, FX
Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective
cross-sectional worldwide study
Lancet Oncology
Castellsague, E; Gonzalez, S; Guino, E; Stevens, KN; Borras, E; Raymond, VM; Lazaro, C;
Blanco, I; Gruber, SB; Capella, G
Allele-Specific Expression of APC in Adenomatous Polyposis Families
Javierre, BM; Fernandez, AF; Richter, J; Al-Shahrour, F; Martin-Subero, JI; Rodriguez-
Ubreva, J; Berdasco, M; Fraga, MF; O’Hanlon, TP; Rider, LG; Jacinto, FV; Lopez-Longo,
FJ; Dopazo, J; Forn, M; Peinado, MA; Carreno, L; Sawalha, AH; Harley, JB; Siebert, R;
Esteller, M; Miller, FW; Ballestar, E
Changes in the pattern of DNA methylation associate with twin discordance in systemic
lupus erythematosus
Genome Research
Santidrian, AF; Gonzalez-Girones, DM; Iglesias-Serret, D; Coll-Mulet, L; Cosialls, AM; de
Frias, M; Campas, C; Gonzalez-Barca, E; Alonso, E; Labi, V; Viollet, B; Benito, A; Pons,
G; Villunger, A; Gil, J
AICAR induces apoptosis independently of AMPK and p53 through up-regulation of the
BH3-only proteins BIM and NOXA in chronic lymphocytic leukemia cells
Caro-Maldonado, A; Tait, SWG; Ramirez-Peinado, S; Ricci, JE; Fabregat, I; Green, DR;
Munoz-Pinedo, C
Glucose deprivation induces an atypical form of apoptosis mediated by caspase-8 in
Bax-, Bak-deficient cells
Cell Death and Differentiation
Schluter, A; Real-Chicharro, A; Gabaldon, T; Sanchez-Jimenez, F; Pujol, A
PeroxisomeDB 2.0: an integrative view of the global peroxisomal metabolome
Nucleic Acids Research
Aguilar, H; Sole, X; Bonifaci, N; Serra-Musach, J; Islam, A; Lopez-Bigas, N; Mendez-
Pertuz, M; Beijersbergen, RL; Lazaro, C; Urruticoechea, A; Pujana, MA
Biological reprogramming in acquired resistance to endocrine therapy of breast cancer
Garcia-Vidal, C; Ardanuy, C; Tubau, F; Viasus, D; Dorca, J; Linares, J; Gudiol, F; Carratala, J
Pneumococcal pneumonia presenting with septic shock: host- and pathogen-related
factors and outcomes
Lopez-Sola, M; Pujol, J; Hernandez-Ribas, R; Harrison, BJ; Contreras-Rodriguez, O;
Soriano-Mas, C; Deus, J; Ortiz, H; Menchon, JM; Vallejo, J; Cardoner, N
Effects of Duloxetine Treatment on Brain Response to Painful Stimulation in Major
Depressive Disorder
Rodriguez-Nieto S, Cañada A, Pros E, Pinto AI, Torres-Lanzas J, Lopez-Rios F, Sanchez-
Verde L, Pisano DG, Sanchez-Cespedes M.
Massive parallel DNA pyrosequencing analysis of the tumor suppressor BRG1/
SMARCA4 in lung primary tumors.
Human Mutation
Durrbach, A; Pestana, JM; Pearson, T; Vincenti, F; Garcia, VD; Campistol, J; Rial, MD;
Florman, S; Block, A; Di Russo, G; Xing, J; Garg, P; Grinyo, J
A Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplants from Extended
Criteria Donors (BENEFIT-EXT Study)
American Journal of Transplantation
Gomez, A; Ferrer, I
Involvement of the cerebral cortex in Parkinson disease linked with G2019S LRRK2
mutation without cognitive impairment
Acta Neuropathologica
Guedan, S; Rojas, JJ; Gros, A; Mercade, E; Cascallo, M; Alemany, R
Hyaluronidase Expression by an Oncolytic Adenovirus Enhances Its Intratumoral
Spread and Suppresses Tumor Growth
Molecular Therapy
Rodríguez-Carballo E, Ulsamer A, Susperregui AR, Manzanares-Céspedes C, Sánchez-
García E, Bartrons R, Rosa JL, Ventura F.
Conserved regulatory motifs in osteogenic gene promoters integrate cooperative
effects of canonical Wnt and BMP pathways.
Journal of Bone and Mineral Research
Regidor, E; Gutierrez-Fisac, JL; Ichaso, MD; Fernandez, E
Trends in principal cancer risk factors in Spain
Annals of Oncology
Duell, EJ; Travier, N; Lujan-Barroso, L; Boutron-Ruault, MC; Clavel-Chapelon, F; Palli,
D; Krogh, V; Mattiello, A; Tumino, R; Sacerdote, C; Rodriguez, L; Sanchez-Cantalejo, E;
Navarro, C; Barricarte, A; Dorronsoro, M; Khaw, KT; Wareham, N; Allen, NE; Tsilidis,
KK; Bueno-De-Mesquita, HB; Jeurnink, SM; Numans, ME; Peeters, PHM; Lagiou, P;
Valanou, E; Trichopoulou, A; Kaaks, R; Lukanova-McGregor, A; Bergman, MM; Boeing,
H; Manjer, J; Lindkvist, B; Stenling, R; Hallmans, G; Dahm, CC; Overvad, K; Olsen, A;
Tjonneland, A; Bakken, K; Lund, E; Jenab, M; McCormack, V; Rinaldi, S; Michaud, D;
Mouw, T; Nesi, G; Carneiro, F; Riboli, E; Gonzalez, CA
Menstrual and Reproductive Factors, Exogenous Hormone Use, and Gastric Cancer
Risk in a Cohort of Women From the European Prospective Investigation Into Cancer
and Nutrition
American Journal of Epidemiology
Sancho, P; Fabregat, I
NADPH Oxidase NOX1 Controls Autocrine Growth of Liver Tumor Cells through Up-
regulation of the Epidermal Growth Factor Receptor Pathway
Journal of Biological Chemistry
Who we are
Qui som
Quiénes somos
Our research
La nostra recerca
Nuestra investigación
Cancer and Human Molecular Genetics
Cancer Virotherapy | Cell Death Regulation | Virus and Cancer | Hereditary Cancer
| Biological Clues of the Invasive and Metastasic Phenotype | Cancer Control and
Prevention | Hematopoyetic and Lymphoid Tumours | Clinical Research, Applied
Radiobiology and Experimental Radiotherapy | Nutrition, Environment and Cancer |
Sarcomas | Colorectal Cancer | Apoptosis and Cancer | Human Molecular Genetics
MARIONA FONT-LLITJÓS | Palliative Care | Breast Cancer | Chemoresistance and Predictive Factors to Tumour
Response and Stromal Microenvironment |Tumour Angiogenesis
Neurologic Diseases and Neurogenetics | Neurometabolic Diseases | Cognition and
Brain Plasticity | Neuropathology | Toxicity of Sensorial and Motor Systems | Psychiatry
and Mental Health | Neuropharmacology and Pain | Perisurgical Physiopathology and
Pain | Cellular and Molecular Neurobiology
Infectious Pathology and Transplants
Nephrology and Renal Transplantation | Infectious Disease and Microbial Drug
Resistance | New Therapies on Genes and Transplantation
Growth Factors, Hormones and Diabetes
Diabetes, Nutrition and Endocrinological Diseases | Nutrition, Metabolism and Gene
Therapy | Growth Factors and Cellular Differentiation
Inflammatory, Chronic and Degenerative Diseases
IDIBELL is a research centre Pneumology | Digestive Tract Pathology | Hepato-biliary-pancreatic Pathology |
focused on cellular medicine, Cardiovascular Diseases | Image Diagnosis and Nuclear Medicine | Cardiovascular
Diseases | Head and Neck Diseases | Odontological and Maxillofacial Pathology and
where the high level basic Therapeutics | Robotics Surgery | Synovial Inflammation and Bone Metabolism |
research focuses and works on Clinical Prevention
relevant clinical matters and the
economic development Epigenetics and Cancer Biology
Cancer Epigenetics | Genes and Cancer | Chromatin and Disease | Ageing and Cancer |
IDIBELL és un centre de recerca Genomic Imprint and Cancer | Transformation and Metastasis | Cell Cycle | Chromatin
en medicina cel·lular on la Biology | Cellular Differenciation
investigació bàsica d’alt nivell
està al servei de preguntes
clíniques rellevants i del
desenvolupament econòmic
IDIBELL es un centro de
investigación en medicina celular
donde la investigación básica
de alto nivel está al servicio de
preguntas clínicas relevantes y
del desarrollo económico
© 2011 Institut d’Investigació Biomèdica de Bellvitge (IDIBELL)
Granvia de l’Hospitalet, 199-203
08908 L’Hospitalet de Llobregat. Barcelona. Spain
Telephone 93 260 74 11
E-mail [email protected]
www.idibell.cat · www.facebook.com/Idibell · www.twitter.com/idibell_en

Use: 0.1139